Literature DB >> 14699462

Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.

Prema Gurumurthy1, Geetha Ramachandran, A K Hemanth Kumar, S Rajasekaran, C Padmapriyadarsini, Soumya Swaminathan, P Venkatesan, L Sekar, S Kumar, O R Krishnarajasekhar, P Paramesh.   

Abstract

The absorption of rifampin, isoniazid, and D-xylose in patients with human immunodeficiency virus (HIV) infection and diarrhea, in patients with HIV infection and tuberculosis (TB), in patients with pulmonary TB alone, and in healthy subjects was studied. Percentage of dose of the drugs, their metabolites, and D-xylose excreted in urine were calculated. A significant reduction in the absorption of drugs and D-xylose in both the HIV infection/diarrhea and HIV infection/TB groups was observed (P<.05), and the correlation between them was significant. Our results indicate that patients with HIV infection and diarrhea and those with HIV infection and TB have malabsorption of rifampin and isoniazid.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14699462     DOI: 10.1086/380795

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

1.  Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.

Authors:  Stephanie Thee; Anthony J Garcia-Prats; Heather R Draper; Helen M McIlleron; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling
Journal:  Clin Infect Dis       Date:  2014-10-30       Impact factor: 9.079

2.  AIDS diarrhea and antiretroviral drug concentrations: a matched-pair cohort study in Port au Prince, Haiti.

Authors:  Rebecca Dillingham; Paul Leger; Carole-Anne Beauharnais; Erica Miller; Angela Kashuba; Steven Jennings; Kathryn Dupnik; Amidou Samie; Etna Eyma; Richard Guerrant; Jean Pape; Daniel Fitzgerald
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

3.  Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

Authors:  S M Graham; D J Bell; S Nyirongo; R Hartkoorn; S A Ward; E M Molyneux
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

5.  Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study.

Authors:  Kathrin Zürcher; Marie Ballif; Lukas Fenner; Sonia Borrell; Peter M Keller; Joachim Gnokoro; Olivier Marcy; Marcel Yotebieng; Lameck Diero; E Jane Carter; Neesha Rockwood; Robert J Wilkinson; Helen Cox; Nicholas Ezati; Alash'le G Abimiku; Jimena Collantes; Anchalee Avihingsanon; Kamon Kawkitinarong; Miriam Reinhard; Rico Hömke; Robin Huebner; Sebastien Gagneux; Erik C Böttger; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2019-02-08       Impact factor: 25.071

6.  Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.

Authors:  Chao Zhang; Paolo Denti; Eric H Decloedt; Yuan Ren; Mats O Karlsson; Helen McIlleron
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

Review 7.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

8.  Drug-resistant tuberculosis: what are the treatment options?

Authors:  Amr S Albanna; Dick Menzies
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

9.  Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.

Authors:  S Thee; A J Garcia-Prats; H M McIlleron; L Wiesner; S Castel; J Norman; H R Draper; P L van der Merwe; A C Hesseling; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

10.  Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation.

Authors:  Awewura Kwara; Margaret Lartey; Isaac Boamah; Naser L Rezk; Joseph Oliver-Commey; Ernest Kenu; Angela D M Kashuba; Michael H Court
Journal:  J Clin Pharmacol       Date:  2009-07-23       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.